Amgen's $14.30 Billion Trading Day Sees 40th Ranking Amidst Stock Decline

On June 23, 2025, Amgen's trading volume reached $14.30 billion, a 27.53% decrease from the previous day, ranking 40th in the day's stock market. Amgen's stock price fell by 5.83%, marking the fourth consecutive day of decline, with a total decrease of 7.82% over the past four days.

Amgen's Phase 2 obesity study demonstrated significant results with its drug MariTide, showing an average weight loss of approximately 20% in individuals with obesity who do not have Type 2 diabetes. This finding is particularly noteworthy as it indicates the potential for further weight loss beyond the 52-week trial period.

However, the study also revealed a high rate of side effects and discontinuations, which could impact the drug's marketability and patient adherence. Despite these challenges, Amgen is expanding its development plans for MariTide, aiming to study its use for heart disease and sleep apnea.

The company plans to initiate a third phase of trials lasting 72 weeks to evaluate the safety, efficacy, and tolerability of MariTide for overweight and obese patients with and without Type 2 diabetes. Additionally, Amgen expects to start Phase 3 studies for atherosclerotic cardiovascular disease, heart failure, and obstructive sleep apnea in 2025.